Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction

Journal of Clinical Oncology

Volumn 20, Issue 21, 2002, Pages 4303-4312

  Raymond, Eric ^a   Boige, Valérie ^a   Faivre, Sandrine ^a   Sanderink, Ger Jan ^a   Rixe, Olivier ^a   Vernillet, Laurent ^a   Jacques, Christian ^a   Gatineau, Michel ^a   Ducreux, Michel ^a   Armand, Jean Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIC ACID; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ATROPINE; BILIRUBIN; CAMPTOTHECIN DERIVATIVE; DRUG METABOLITE; GRANISETRON; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; ONDANSETRON; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER PATIENT; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG CLEARANCE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; SYNDROME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIRUBIN; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; HYPERBILIRUBINEMIA; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 0036843113     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.03.123     Document Type: Article

References (27)

1. Jaxel C, Kohn KW, Wani MC, et al: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and relation to antitumor activity. Cancer Res 49:1465-1469, 1989
2. Bissery MC, Vrignaud P, Lavelle F, et al: Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice. Ann N Y Acad Sci 803:173-180, 1996
3. Zamboni WC, Stewart CF, Cheshire PJ, et al: Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 4:743-753, 1998
4. Vanhoefer U, Harstrick A, Achterrath W, et al: Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 19:1501-1518, 2001
5. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure inpatients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
6. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
7. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
8. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
9. Mathijssen RHJ, van Alphen RJ, Verweij J, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194, 2001
10. Rivory LP, Riou JF, Haaz MC, et al: Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 56:3689-3694, 1996
11. Rivory LP, Haaz MC, Canal P, et al: Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 3:1261-1266, 1997
12. Lokiec F, Monegier du Sorbier B, et al: Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 2:1943-1949, 1996
13. Haaz MC, Rivory L, Riche C, et al: Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468-472, 1998
14. Dodds HM, Haaz MC, Riou JF, et al: Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 286:578-583, 1998
15. Slatter JG, Su P, Sams JP, et al: Bioactivation of the anticancer agent CPT-11 to SN38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157-1164, 1997
16. Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994
17. Araki E, Ishikawa M, Iigo M, et al: Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697-702, 1993
18. Kudoh S, Fukuoka M, Masuda N, et al: Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 86:406-413, 1995
19. Iyer L, Hall D, Das S, et al: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582, 1999
20. Wasserman E, Mijara A, Lokiec F, et al: Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports. Ann Oncol 8:1049-1051, 1997
21. Wasserman E, Myara A, Lokiec F, et al: Bilirubin (BIL) and SN-38: Pharmacokinetic/pharmacodynamic correlation. Ann Oncol 8:1049-1051, 1998
22. Cohen AM, Shank B, Friedman MA: Colorectal cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989, pp 895-964
23. Van Groeningen CJ, van der Vijgh WJF, Baars JJ, et al: Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: A need for guidelines. Clin Cancer Res 6:1342-1346, 2000
24. Ong SY, Clarke SJ, Bishop J, et al: Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anticancer Drugs 12:619-625, 2001
25. Abigerges D, Chabot GG, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
26. Barilero I, Gandia D, Armand JP, et al: Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: Application to plasma pharmacokinetic studies in cancer patients. J Chromatogr 575:275-280, 1992
27. Burke TG, Mi Z: The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. J Med Chem 7:40-46, 1994